Articles dans des revues avec comité de lecture (39)
  1. 1. Woodcock, D. D., Sahli, A., Teslo, R., Bhandari, V., Gruber, A. A., Ziubroniewicz, A., Gundem, G., Xu, Y., Butler, A., Anokian, E., Pope, B. B., Jung, C. H., Tarabichi, M., Dentro, S. S., Farmery, J. J., Van Loo, P., Warren, A. Y., Gnanapragasam, V., Hamdy, F., Bova, G. S., Foster, C., Neal, D. D., Lu, Y. J., Kote-Jarai, Z., Fraser, M., Bristow, R. R., Boutros, P. P., Costello, A. A., Corcoran, N., Hovens, C. C., Massie, C. C., Lynch, A. G., Brewer, D., Eeles, R., Cooper, C., & Wedge, D. (2024). Genomic evolution shapes prostate cancer disease type. Cell Genomics, 4(3), 100511. doi:10.1016/j.xgen.2024.100511
  2. 2. Pita, J. M., Raspé, E., Coulonval, K., Decaussin-Petrucci, M., Tarabichi, M., Dom, G., Libert, F., Ruscas-Craciun, L. I., Andry, G., Wicquart, L., Leteurtre, E., Tresallet, C., Marlow, L. A., Copland, J. A., Durante, C., Maenhaut, C., Cavaco, B. M., Dumont, J. E., Costante, G., & Roger, P. P. (2023). CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas. Frontiers in endocrinology, 14, 1247542. doi:10.3389/fendo.2023.1247542
  3. 3. Kaufmann, T., Petkovic, M., Watkins, T. B. K., Colliver, E., Laskina, S., Thapa, N., Minussi, D., Navin, N., Swanton, C., Van Loo, P., Haase, K., Tarabichi, M., & Schwarz, R. F. (2022). MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution. Genome biology, 23(1). doi:10.1186/s13059-022-02794-9
  4. 4. Paternot, S., Raspé, E., Meiller, C., Tarabichi, M., Assié, J.-B., Libert, F., Remmelink, M., Bisteau, X., Pauwels, P., Blum, Y., Le Stang, N., TABONE-EGLINGER, S., Galateau-Salle, F., Blanquart, C., van Meerbeeck, J. P., Berghmans, T., Jean, D., & Roger, P. P. (2022). Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition. Molecular Oncology. doi:https://doi.org/10.1002/1878-0261.13351
  5. 5. Drews, R. M., Hernando, B., Tarabichi, M., Haase, K., Lesluyes, T., Smith, P. S., Morrill Gavarró, L., Couturier, D. L., Liu, L., Schneider, M., Brenton, J. D., Van Loo, P., Macintyre, G., & Markowetz, F. (2022). A pan-cancer compendium of chromosomal instability. Nature (London), 606(7916), 976-983. doi:10.1038/s41586-022-04789-9
  6. 6. Steele, C. D., Abbasi, A., Islam, S. M. A., Bowes, A. L., Khandekar, A., Haase, K., Hames-Fathi, S., Ajayi, D., Verfaillie, A., Dhami, P., McLatchie, A., Lechner, M., Light, N., Shlien, A., Malkin, D., Feber, A., Proszek, P., Lesluyes, T., Mertens, F., Flanagan, A. M., Tarabichi, M., Van Loo, P., Alexandrov, L. B., & Pillay, N. (2022). Signatures of copy number alterations in human cancer. Nature (London), 606(7916), 984-991. doi:10.1038/s41586-022-04738-6
  7. 7. Bowes, A. A., Tarabichi, M., Pillay, N., & Van Loo, P. (2022). Leveraging single-cell sequencing to unravel intratumour heterogeneity and tumour evolution in human cancers. Journal of pathology. doi:10.1002/path.5914
  8. 8. Zoumpoulidou, G., Alvarez-Mendoza, C., Mancusi, C., Ahmed, R. M., Denman, M., Steele, C. C., Tarabichi, M., Roy, E., Davies, L. L., Manji, J., Cristalli, C., Scotlandi, K., Pillay, N., Strauss, S. J., & Mittnacht, S. (2021). Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma. Nature communications, 12(1), 7064. doi:10.1038/s41467-021-27291-8
  9. 9. Tarabichi, M., Demetter, P., Ruscas-Craciun, L. I., Maenhaut, C., & Detours, V. (2021). Thyroid cancer under the scope of emerging technologies. Molecular and cellular endocrinology, 541, 111491. doi:10.1016/j.mce.2021.111491
  10. 10. Yan, H., Tarabichi, M., McGranahan, N., & Van Loo, P. (2021). DeCiFering the subclonal composition of tumors. Animal Cells and Systems, 12(10), 955-957. doi:10.1016/j.cels.2021.09.008
  11. 11. Steele, C. D., Abbasi, A., S. M. Ashiqul, I., Khandekar, A., Haase, K., Hames, S., Tarabichi, M., Lesluyes, T., Flanagan, A. M., Mertens, F., Van Loo, P., Alexandrov, L. B., & Pillay, N. (2021). Signatures of copy number alterations in human cancer. BioRxiv. doi:10.1101/2021.04.30.441940
  12. 12. Dentro, S. C., Leshchiner, I., Haase, K., Tarabichi, M., Wintersinger, J. J., Deshwar, A. G., Yu, K., Rubanova, Y., Macintyre, G., Demeulemeester, J., Vázquez-García, I., Kleinheinz, K., Livitz, D. G., Malikic, S., Donmez, N., Sengupta, S., Anur, P., Jolly, C., Cmero, M., Rosebrock, D., Schumacher, S., Fan, Y., Fittall, M., Drews, R. M., Yao, X., Watkins, T. B. K., Lee, J., Schlesner, M., Zhu, H., Adams, D. J., McGranahan, N., Swanton, C., Getz, G., Boutros, P. C., Imielinski, M., Beroukhim, R., Sahinalp, C., Ji, Y., Peifer, M., Martincorena, I., Markowetz, F., Mustonen, V., Yuan, K., Gerstung, M., Spellman, P. T., Wang, W., Morris, Q. D., Wedge, D. C., & Van Loo, P. (2021). Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell, 184(8), 2239-2254.e39. doi:10.1016/j.cell.2021.03.009
    13. << Précédent 1 2 3 4 Suivant >>